Company |
Type of |
Number of |
Amount |
Investors; placement agents; details |
Date |
TOTAL: $391.11M | |||||
Aeolus Pharmaceuticals Inc. (Mission Viejo, Calif.) |
Private placement |
N/A |
$6.75 |
Aeolus raised $6.75M in a private placement from new and existing investors, including BVF Partners LP ($4.5M of preferred units) |
12/15/15 |
Agile Therapeutics Inc. (Princeton, N.J.) |
Nondilutive financing through New Jersey's technology business tax certificate transfer program |
N/A |
$6 |
Agile received $6M in net proceeds through the program, which enables companies to sell their unused net operating loss carryovers and unused R&D tax credits for at least 80% of their value to unaffiliated, profitable corporate taxpayers in the state |
12/2/15 |
Antibe Therapeutics Inc. (Toronto) |
Private placement |
45U |
$0.45 |
Antibe completed the first closing of a brokered private placement on the same financial terms as the previously disclosed nonbrokered private placement completed in connection with the acquisition of Citagenix Inc.; the placement of 45 units yielded $450,000 gross; Bloom Burton & Co. Ltd. acted as the agent in the deal |
12/28/15 |
Antriabio Inc. (Louisville, Colo.) |
Private placement |
7.7S of series A preferred |
$2 |
Antriabio closed the first $2M of a planned $15M private placement in which it is issuing up to 7.7M shares of series A preferred stock at $1.95 per share |
12/11/15 |
Bionomics Ltd. (Australia) |
Private placement |
40.2S |
$12 |
Bionomics raised $12M in a private placement to four U.S. institutional investors; Roth Capital Partners acted as the sole U.S. placement agent |
12/9/15 |
Biopharmx Corp. (Menlo Park, Calif.) |
Private placement |
4.1S |
$5.9 |
Biopharmx raised $5.9M through the sale of 4.1M shares priced at $1.43 per share to investment vehicles of Franklin Advisers |
12/14/15 |
Checkpoint Therapeutics Inc. (New York; a Fortress Biotech Inc. company) |
Private placement of units |
Units |
$58 |
Checkpoint raised $58M in a series of private placement financings of units, each consisting of 10,000 shares of common stock and a warrant exercisable for 2,500 shares of common stock at $7 per share, for a purchase price of $50,000 per unit |
12/22/15 |
Diurnal plc (Cardiff, UK) |
Loan |
N/A |
$5.16 |
Diurnal received a £4.7M (US$5.16M) convertible loan through IP2IPO Limited |
12/22/15 |
Erytech Pharma SA (Lyon, France) |
Private placement |
0.94S |
$27.6 |
Erytech closed a private placement of 940,000 shares to qualified investors in the U.S. and Europe for a total of €25.4M (US$27.6M) |
12/8/15 |
Genspera Inc. (San Antonio) |
Private placement of shares of convertible preferred stock and warrants |
N/A |
$2.5 |
Genspera entered definitive agreements with institutional investors, led by an undisclosed health care-dedicated fund, for a private placement raising $2.5M; H.C. Wainwright & Co. acted as the exclusive placement agent |
12/28/15 |
Kalobios Pharmaceuticals Inc. (South San Francisco) |
Private placement |
N/A |
$8.2 |
Kalobios entered definitive agreements with institutional and accredited investors in connection with a private placement in which it expects to receive gross proceeds of about $8.2M |
12/7/15 |
Merrimack Pharmaceuticals Inc. (Cambridge, Mass.) |
Private placement of senior secured notes due 2022 |
N/A |
$175 |
Merrimack closed the placement of $175M in senior secured notes due 2022, which bear an interest rate of 11.5% annually; a portion of the proceeds will repay debt with Hercules Technology Growth Capital Inc. |
12/24/15 |
Northwest Biotherapeutics Inc. (Bethesda, Md.) |
Registered direct offering |
3.5S and W for 1.75S |
$12.6 |
Northwest raised $12.6M through the offering of 3.5M shares at $3.60 each, plus warrants to purchase up to 1.75M shares of common stock with an exercise price of $4.50 per share |
12/24/15 |
Orgenesis Inc. (Germantown, Md.) |
Equity financing |
8.2S and 8.2W |
$10 |
Orgenesis raised and fulfilled its obligation for a $10M debt or equity financing, selling units at 52 cents each |
12/17/15 |
Oryzon Genomics SA (Barcelona, Spain) |
Loans |
N/A |
$1.3 |
Oryzon was granted two unsecured 10-year concessional loans from Spain's Ministry of Economy and Competitiveness |
12/31/15 |
Soligenix Inc. (Princeton, N.J.) |
New Jersey's Technology Business Tax Certificate Transfer Program financing |
N/A |
$0.49 |
Soligenix received about $490,000 in a nondilutive financing by selling unused net operating loss carryovers and unused R&D tax credits to unaffiliated, profitable corporate taxpayers in New Jersey |
12/10/15 |
Starpharma Holdings Ltd. (Melbourne, Australia) |
Private placement |
N/A |
$23 |
Starpharma raised A$32M (US$23.1M) via a private placement to domestic and international institutional investors; Bell Potter Securities Ltd. and Canaccord Genuity acted as joint lead managers |
12/10/15 |
Tiziana Life Sciences plc (London) |
Private placement of unsecured convertible loan notes |
2.6 loan notes |
$5.7 |
Tiziana raised about £3.8M (US$5.7M) through the issue of about 2.6M unsecured convertible loan notes to investors |
12/9/15 |
Txcell SA (Valbonne, France) |
Equity facility |
1.15W |
ND |
Txcell implemented a standby equity facility with Societe Generale, by way of issuance of 1.15M warrants |
12/23/15 |
Viralytics Ltd. (Sydney) |
Private placement |
46.1S |
$28 |
Viralytics completed a placement of 46.1M shares at $0.615 each to generate $28.36M from Orbimed Advisors, Biotechnology Value Fund LP and other affiliates BVF Partners LP |
12/15/15 |
|
Notes This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. N/A = Not applicable; ND = Not disclosed. This chart includes only biotech companies that develop therapeutics. | |||||